文献速递炎症性肠病

乌司奴单抗在克罗恩病患者中的药代动力学及暴露-反应关系

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
PubMed 文献 · Gastroenterology · 2018-02-01

该分析汇集2项3期诱导研究和1项维持研究中乌司奴单抗的血清浓度与疗效数据,显示血清浓度与剂量成比例,且与临床缓解和内镜疗效相关;谷浓度≥0.8(甚至可达1.4)μg/mL者维持临床缓解的比例更高。

要点

  • 乌司奴单抗血清浓度与剂量成比例,两项诱导研究间无显著差异。
  • 维持研究中8周间隔给药的中位谷浓度约为12周间隔给药的3倍。
  • 谷浓度≥0.8(或甚至高达1.4)μg/mL者维持临床缓解的比例高于谷浓度较低者。

核心结论

  • 在针对中重度克罗恩病患者的3期研究数据分析中,乌司奴单抗血清浓度与剂量成比例并与治疗疗效相关。
  • 乌司奴单抗浓度似乎不受免疫调节剂联合治疗的影响。

研究设计与样本

  • 收集2项3期诱导研究和1项维持研究的数据,以确定乌司奴单抗的药代动力学特征、暴露与反应的关系及疗效的最佳血清浓度。
  • 诱导研究:中重度克罗恩病患者接受单次静脉剂量(130 mg或约6 mg/kg)后观察8周。
  • 维持研究:诱导研究中有反应的患者接受皮下注射(90 mg)每8周或每12周一次,持续44周。
  • 维持研究第44周(治疗开始后52周)评估主要终点临床缓解(克罗恩病活动指数评分低于150分)、内镜疗效指标和血清C反应蛋白水平。
  • 乌司奴单抗浓度数据按四分位数分类,评估暴露与反应的关系;使用受试者工作特征曲线分析评估最佳浓度截断值。

主要发现

  • 乌司奴单抗血清浓度随时间与剂量成比例,两项诱导研究间无显著差异。
  • 维持研究中,乌司奴单抗浓度在第二次维持剂量时达到稳态;8周间隔给药患者的中位谷浓度约为12周间隔给药患者的3倍。
  • 乌司奴单抗血清浓度与临床缓解率和内镜疗效终点相关,与C反应蛋白水平呈负相关,与免疫调节剂使用无关。
  • 乌司奴单抗谷浓度≥0.8(或甚至高达1.4)μg/mL者维持临床缓解的比例高于谷浓度较低者。

关键数值与推荐

  • 临床缓解定义为克罗恩病活动指数评分低于150分。
  • 诱导研究静脉剂量为130 mg或约6 mg/kg。
  • 维持研究皮下注射剂量为90 mg,每8周或每12周一次,持续44周。
  • 谷浓度≥0.8(或甚至高达1.4)μg/mL与更高比例的临床缓解维持相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD). However, there are few data on its pharmacokinetic properties or the relationship between drug exposure levels and patient response. We collected data from 2 Phase 3 induction studies and 1 maintenance study to determine ustekinumab's pharmacokinetic features, relationship between exposure and response, and optimal serum concentrations for efficacy. METHODS: We collected data on serum concentrations of ustekinumab and efficacy from induction studies of patients with moderate to severe CD given ustekinumab for 8 weeks following a single intravenous dose (either 130 mg or approximately 6 mg/kg). We collected the same data from a maintenance study of patients with a response to ustekinumab in the induction study who then received subcutaneous injections (90 mg) every 8 or 12 weeks for 44 weeks. At week 44 of the maintenance study (52 weeks after treatment began), patients were evaluated for the primary endpoint of clinical remission (defined as a CD activity index score below 150 points), endoscopic markers of efficacy, and serum level of C-reactive protein. Ustekinumab concentration data were categorized into quartiles and relationships between exposure and response were assessed. Optimal concentration cutoff values were evaluated using receiver operating characteristic curve analysis. RESULTS: Serum concentrations of ustekinumab over time were proportional to dose and did not differ significantly between the induction studies. In the maintenance study, ustekinumab concentration reached the steady state by the second maintenance dose; the median trough concentration was approximately threefold higher in patients given ustekinumab at 8-week intervals compared with 12-week intervals. Ustekinumab serum concentrations associated with rates of clinical remission and endoscopic efficacy endpoints, correlated inversely with level of C-reactive protein, and did not associate with use of immunomodulators. Trough concentrations of ustekinumab of 0.8 (or even up to 1.4 μg/mL) or greater were associated with maintenance of clinical remission in a higher proportion of patients than patients with lower trough concentrations. CONCLUSIONS: In an analysis of data from Phase 3 studies of patients with moderate to severe CD, we found serum concentrations of ustekinumab to be proportional to dose and associate with treatment efficacy. Concentrations of ustekinumab did not seem to be affected by cotreatment with immunomodulators. Clinicaltrials.gov no. NCT01369329 (UNITI 1), NCT01369342 (UNITI 2), and NCT01369355 (IM-UNITI).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018. PMID: 29409871. doi:10.1053/j.gastro.2018.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。